The Food and Drug Administration (FDA) has granted Prior Approval Supplement (PAS) not to Zydus Lifesciences to market its generic version of Mycophenolate Mofetil of injection. Mycophenolate Mofetil (CellCept) is used with other drugs as prophylaxis of organ rejection in patients who undergo kidney, liver, or heart transplants.